Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
? Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments...






